We continuously develop and expand our robust pipeline to address patients' unmet medical needs. Our pursuit of new medicines is fueled by the scientific curiosity of our employees, a willingness to examine new ideas, and the pairing of existing information with novel concepts.

Please note that the medicines in the pipeline below are currently under clinical trial investigation and are not yet approved.

Pipeline Chart

* As of January 2021

Pipeline Chart(486KB)

3 ADCs

  • DS-8201
  • U3-1402
  • DS-1062

BC: breast cancer, CRC: colorectal cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, TNBC: triple negative breast cancer

  • : Breakthrough Designation (US), SAKIGAKE Designation (JP)
  • : Orphan drug designation (JP/US/EU)

Phase 1

  • DS-1062 (JP/US)
    NSCLC, TNBC
    TROPION-PanTumor01
  • DS-1062 (JP/US)
    NSCLC (without actionable mutation, pembrolizumab combo)
    TROPION-Lung02
  • DS-1062 (JP/US)
    NSCLC (without actionable mutation, durvalumab combo)
    TROPION-Lung04
  • U3-1402 (JP/US/EU/Asia)
    NSCLC
  • U3-1402 (JP/US)
    EGFRm NSCLC (osimertinib combo)
  • U3-1402 (JP/US)
    HER3+ BC
  • DS-8201 (US/EU/Asia)
    HER2+ BC 2L~/1L
    DESTINY-Breast07
  • DS-8201 (US/EU/Asia)
    HER2 low BC chemo naive/post chemo
    DESTINY-Breast08
  • DS-8201 (US/EU/Asia)
    HER2+ GC combo 2L~/1L
    DESTINY-Gastric03
  • DS-8201 (EU/Asia)
    HER2+ NSCLC (durvalumab combo)
    DESTINY-Lung03
  • DS-8201 (US/EU)
    BC, bladder cancer (nivolumab combo)
  • DS-8201 (US/EU)
    BC, NSCLC (pembrolizumab combo)

Phase 2

  • DS-8201 (US/EU/Asia)
    TNBC (durvalumab combo)
    BEGONIA
  • DS-8201 (US/EU)
    HER2+ GC 2L
    DESTINY-Gastric02
  • DS-8201 (JP/US/EU)
    HER2+/m NSCLC
    DESTINY-Lung01
  • DS-8201 (JP/US/EU)
    HER2+/m NSCLC
    DESTINY-Lung02
  • DS-8201 (US/EU/Asia)
    NSCLC (durvalumab combo)
    HUDSON
  • DS-8201 (JP/US/EU)
    HER2+ CRC
    DESTINY-CRC01
  • DS-8201 (US/EU/Asia)
    HER2 mutated tumor
    DESTINY-PanTumor01
  • DS-8201 (US/EU/Asia)
    HER2 expressing tumors
    DESTINY-PanTumor02
  • DS-1062 (JP/US/EU/Asia)
    NSCLC (with actionable mutation)
    TROPION-Lung05
  • U3-1402 (JP/US)
    EGFRm NSCLC
    HERTHENA-Lung01
  • U3-1402 (JP/US/EU)
    HER3+ CRC

Phase 3

  • DS-8201 (JP/US/EU/Asia)
    HER2+ BC 3L
    DESTINY-Breast02
  • DS-8201 (JP/US/EU/Asia)
    HER2+ BC 2L
    DESTINY-Breast03
  • DS-8201 (JP/US/EU/Asia)
    HER2 low BC post chemo
    DESTINY-Breast04
  • DS-8201 (JP/US/EU/Asia)
    HER2+ BC post neoadjuvant
    DESTINY-Breast05
  • DS-8201 (JP/US/EU/Asia)
    HER2 low BC chemo naive
    DESTINY-Breast06
  • DS-8201 (JP/US/EU/Asia)
    HER2+ GC 2L
    DESTINY-Gastric04
  • DS-1062 (JP/US/EU/Asia)
    NSCLC (without actionable mutation)
    TROPION-Lung01

Alpha

  • Oncology
  • Specialty Medicines
  • Vaccine

AF: atrial fibrillation, ALL: acute lymphocytic leukemia, AML: acute myeloid leukemia, ATL/L: adult T-cell leukemia/lymphoma, DMD: Duchenne muscular dystrophy, GIST: gastrointestinal stromal tumor, IIS: investigator-initiated study, NSCLC: non-small cell lung cancer, PTCL: peripheral T-cell lymphoma

  • : Project in oncology that is planned to be submitted for approval based on the results of phase 2 trials
  • : SAKIGAKE Designation (JP)
  • : Orphan drug designation (JP/US/EU)

Phase 1

  • DS-7300 (JP/US)
    B7-H3-directed ADC
    Solid tumors
  • DS-6157 (JP/US)
    GPR20-directed ADC
    GIST
  • DS-6000 (US)
    CDH6-directed ADC
    Renal cell calcinoma, ovarian cancer
  • DS-1055 (JP/US)
    Anti-GARP antibody
    Solid tumors
  • DS-2741 (JP)
    Anti-Orai1 antibody
    Atopic dermatitis
  • DS-3201 (JP/US)
    EZH1/2 inhibitor
    Non-Hodgkin‘s Lymphomas
  • DS-3201 (US)
    EZH1/2 inhibitor
    AML, ALL
  • PLX2853 (US)
    BET inhibitor
    AML
  • PLX2853 (US)
    BET inhibitor
    Solid tumor
  • PLX2853 (US)
    BET inhibitor
    Gynecologic neoplasms, ovarian cancer
  • PLX2853 (US)
    BET inhibitor
    Prostate cancer

Phase 2

  • DS-3201 (JP)
    EZH1/2 inhibitor
    ATL/L
  • DS-3201 (JP/US/EU/Asia)
    EZH1/2 inhibitor
    PTCL
  • DS-1001 (JP)
    Mutant IDH1 inhibitor
    Glioma
  • DS-5141 (JP)
    ENA oligonucleotide DMD
  • DS-1211 (US)
    TNAP inhibitor
    Pseudoxanthoma elasticum

Phase 3

  • Quizartinib (JP/US/EU/Asia)
    FLT3 inhibitor
    1L AML
    QuANTUM-First
  • Pexidartinib (JP/Asia)
    CSF-1/KIT/FLT3 inhibitor
    Tenosynovial giant cell tumor
  • Mirogabalin (JP/Asia)
    α2δ Ligands
    Central neuropathic pain
  • Esaxerenone (JP)
    MR blocker
    Diabetic nephropathy
  • VN-0102/JVC-001 (JP)
    Measles mumps rubella
    combined vaccine

Submitted

  • DS-1647 (G47Δ) (JP)
    Oncolytic HSV-1
    Malignant glioma
    IIS
  • Edoxaban (JP)
    FXa inhibitor
    AF in the very elderly
  • Prasugrel (JP)
    ADP receptor inhibitor
    Ischemic stroke
  • VN-0107/MEDI3250 (JP)
    Live attenuated influenza vaccine nasal spray